Adaptimmune Therapeutics Résultats passés
Passé contrôle des critères 0/6
Adaptimmune Therapeutics a connu une croissance annuelle moyenne de ses bénéfices de 13.1%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 36.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 47.9% par an.
Informations clés
13.12%
Taux de croissance des bénéfices
24.70%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 47.87% |
| Rendement des fonds propres | -244.01% |
| Marge nette | -1,316.78% |
| Dernière mise à jour des bénéfices | 31 Dec 2025 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Feb 11
ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential
Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).Mise à jour du récit • Jan 26
ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential
Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).Mise à jour du récit • Jan 12
ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.Mise à jour du récit • Dec 16
ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).Mise à jour du récit • Dec 02
ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential
Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.Mise à jour du récit • Nov 18
ADAP.Y: Voluntary SEC Deregistration and Index Removals Will Unlock Future Value
Analysts have raised their price target for Adaptimmune Therapeutics from $0.98 to $1.50. This change reflects updated expectations for valuation and revised future earnings metrics.Mise à jour du récit • Nov 03
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
Analysts have raised the price target for Adaptimmune Therapeutics from $0.64 to $0.98 per share. This change reflects increased optimism on future revenue growth and profit margins, despite a slightly higher discount rate.Mise à jour du récit • Aug 22
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Analysts have lowered their price target for Adaptimmune Therapeutics, citing solvency concerns, ongoing strategic uncertainty, and a lack of near-term catalysts, resulting in a revised fair value from $0.714 to $0.638. Analyst Commentary Bearish analysts cite significant solvency and sustainability concerns, questioning whether the company has sufficient financial resources to navigate near-term challenges.Mise à jour du récit • Aug 07
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Despite a modestly improved revenue growth outlook and a significantly lower forward P/E, consensus analyst sentiment has worsened, leading to a marked price target reduction from $0.96 to $0.714. What's in the News Adaptimmune Therapeutics reached a settlement with MD Anderson Cancer Center to resolve litigation related to a previous strategic alliance, with all claims to be dismissed upon payment.
Nouveau récit • Apr 04
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.Article d’analyse • Mar 11
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders that were waiting for something to happen have been dealt a...Article d’analyse • Jan 01
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%
To the annoyance of some shareholders, Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares are down a considerable 26...Article d’analyse • Dec 15
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Unfortunately for some shareholders, the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) share price has dived 32% in the...Article d’analyse • Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders won't be pleased to see that the share price has had a very...Seeking Alpha • Sep 12
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Summary Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma and a boxed warning for cytokine release syndrome. The U.S. population eligible for Tecelra is small, approximately 100-400 patients, based on various eligibility factors. The collaboration with Galapagos provides $70 million upfront and potential milestone payments up to $465 million, expanding the development of uza-cel in solid tumors. Adaptimmune’s Q2 2024 revenue jumped due to deferred revenue from the terminated Genentech collaboration, resulting in a $69.5 million net profit. Given the limited market and logistical complexities, the likelihood of peak revenue exceeding $200 million is low, presenting high investment risk. Read the full article on Seeking AlphaSeeking Alpha • Jul 03
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Summary Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further. Read the full article on Seeking AlphaSeeking Alpha • Apr 26
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon. Read the full article on Seeking AlphaArticle d’analyse • Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have retraced a considerable 29% in the last month, reversing a...Article d’analyse • Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have continued their recent momentum with a 107% gain in the last...Seeking Alpha • Feb 02
Adaptimmune: Drug Approval Now Imminent?
Summary Adaptimmune's BLA for their T-cell therapy in soft tissue sarcomas has been accepted for review by the FDA. The company's lead candidate, Afami-cel, has shown promising results in synovial sarcoma, with a PDUFA date set for August 4, 2024. Adaptimmune's cash position is low, but expected milestone payments from their collaboration with Genentech may extend their cash runway. Read the full article on Seeking AlphaArticle d’analyse • Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders are no doubt pleased to see that the share price has bounced...Article d’analyse • Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Article d’analyse • Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Shareholders in Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) may be thrilled to learn that the analysts have just...Article d’analyse • Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Article d’analyse • Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 20
Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well.Article d’analyse • Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Adaptimmune Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 25 | 6 | -78 | 36 | 48 |
| 30 Jun 25 | 65 | -170 | 84 | 0 |
| 31 Mar 25 | 180 | -70 | 83 | 0 |
| 31 Dec 24 | 178 | -71 | 81 | 0 |
| 30 Sep 24 | 175 | -45 | 70 | 0 |
| 30 Jun 24 | 141 | -72 | 72 | 0 |
| 31 Mar 24 | 18 | -163 | 70 | 0 |
| 31 Dec 23 | 60 | -114 | 64 | 0 |
| 30 Sep 23 | 71 | -95 | 68 | -105 |
| 30 Jun 23 | 71 | -91 | 61 | 0 |
| 31 Mar 23 | 71 | -114 | 59 | 0 |
| 31 Dec 22 | 27 | -165 | 63 | 0 |
| 30 Sep 22 | 18 | -175 | 63 | 105 |
| 30 Jun 22 | 12 | -176 | 61 | 0 |
| 31 Mar 22 | 9 | -171 | 60 | 0 |
| 31 Dec 21 | 6 | -158 | 57 | 0 |
| 30 Sep 21 | 6 | -156 | 56 | 0 |
| 30 Jun 21 | 6 | -149 | 54 | 0 |
| 31 Mar 21 | 4 | -140 | 50 | 0 |
| 31 Dec 20 | 4 | -130 | 46 | 0 |
| 30 Sep 20 | 3 | -123 | 43 | 0 |
| 30 Jun 20 | 2 | -127 | 41 | 0 |
| 31 Mar 20 | 2 | -138 | 41 | 0 |
| 31 Dec 19 | 1 | -137 | 43 | 0 |
| 30 Sep 19 | 2 | -144 | 43 | 0 |
| 30 Jun 19 | 42 | -99 | 43 | 0 |
| 31 Mar 19 | 51 | -102 | 44 | 0 |
| 31 Dec 18 | 60 | -96 | 44 | 0 |
| 30 Sep 18 | 62 | -87 | 42 | 0 |
| 30 Jun 18 | 49 | -93 | 39 | 0 |
| 31 Mar 18 | 43 | -69 | 36 | -19 |
| 31 Dec 17 | 38 | -70 | 31 | 0 |
| 30 Sep 17 | 42 | -58 | 29 | 17 |
| 30 Jun 17 | 17 | -76 | 26 | 32 |
| 31 Mar 17 | 14 | -78 | 24 | 68 |
| 31 Dec 16 | 14 | -72 | 23 | 0 |
| 30 Sep 16 | 10 | -73 | 23 | 63 |
| 30 Jun 16 | 12 | -61 | 21 | 57 |
| 31 Mar 16 | 15 | -55 | 21 | 48 |
| 31 Dec 15 | 14 | -48 | 18 | 40 |
| 30 Sep 15 | 13 | -19 | 14 | 29 |
| 30 Jun 15 | 10 | -37 | 10 | 24 |
Des revenus de qualité: ADAP.Y n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: ADAP.Y n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ADAP.Y n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 13.1% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de ADAP.Y au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: ADAP.Y n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 54.5% ).
Rendement des fonds propres
ROE élevé: ADAP.Y a un retour sur capitaux propres négatif ( -244.01% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/09 10:12 |
| Cours de l'action en fin de journée | 2026/06/09 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Adaptimmune Therapeutics plc est couverte par 8 analystes. 0 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ying Huang | BofA Global Research |
| Mohit Bansal | Citigroup Inc |
| Reni Benjamin | Raymond James & Associates |